Data Availability
Requests for deidentified patient data by researchers with proposed use of the data can be made to corresponding author with specific data needs, analysis plans and dissemination plans. Those requests will be reviewed by a study steering committee and the study sponsor for release upon publication. Contact: [email protected]
Acknowledgments
The authors wish to express their gratitude to the members of the Data Monitoring and Safety Committee Professors Michael Niederman, Jos WM van der Meer and Konrad Reinhart for their valuable contribution and for their critical review of the submitted manuscript.
Author Contributions
EKy participated in data analysis and drafting the manuscript. MK performed data analysis and revised the manuscript for important intellectual content. GP, HM, SM GA, KT, AF, AR, CD, MF, IK, GCh, GCa, MKo, DMM, VR, SM, MT, AA, IK, ZA, FC, FSS, PB, EN, VT, EKo, LD, PK, KD, GT, MC, MB, KK, VK, GT, CS, IB, MS, MD, SK, AM, IP, AA, CSC, EG, AC, KA, SS, MM, GI, AK, PP, GND recruited patients in the trial, collected data and revised the manuscript for important intellectual content. EIK, OLD, EF, KK collected data and revised the manuscript for important intellectual content. MGN and JEO revised the manuscript for important intellectual content. EJGB conceptualized the study design, participated in data analysis, drafted the manuscript and takes full responsibility of data integrity.
Competing Interests
G. Poulakou has received independent educational grants from Pfizer, MSD, Angelini, and Biorad.
H. Milionis reports receiving honoraria, consulting fees and non-financial support from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer, and Servier.
L. Dagna had received consultation honoraria from SOBI.
M. Bassetti has received funds for research grants and/or advisor/consultant and/or speaker/chairman from Angelini, Astellas, Bayer, Biomerieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, Roche, Shionogi and Nabriva.
M. G. Netea is supported by an ERC Advanced Grant (#833247) and a Spinoza grant of the Netherlands Organization for Scientific Research. He has also received independent educational grants from TTxD, GSK and ViiV HealthCare.
J. Eugen-Olsen is a co-founder, shareholder and CSO of ViroGates, Denmark, and named inventor on patients on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark.
P. Panagopoulos has received honoraria from GILEAD Sciences, Janssen, and MSD.
G. N. Dalekos is an advisor or lecturer for Ipsen, Pfizer, Genkyotex, Novartis, Sobi, received research grants from Abbvie, Gilead and has served as PI in studies for Abbvie, Novartis, Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics Inc, Tiziana Life Sciences, Bayer, Astellas, Pfizer, Amyndas Pharmaceuticals, CymaBay Therapeutics Inc., Sobi and Intercept Pharmaceuticals.
E. J. Giamarellos-Bourboulis has received honoraria from Abbott CH, bioMérieux, Brahms GmbH, GSK, InflaRx GmbH, Sobi and XBiotech Inc; independent educational grants from Abbott CH, AxisShield, bioMérieux Inc, InflaRx GmbH, Johnson & Johnson, MSD, Sobi and XBiotech Inc.; and funding from the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grants ImmunoSep and RISKinCOVID (granted to the Hellenic Institute for the Study of Sepsis).
The other authors do not have any competing interest to declare.